Structure-Based Design of a Highly Potent Dual-Competitive FTO Inhibitor for Targeted m⁶A Demethylase Inhibition in...

Area of Science:

• Biochemistry and Molecular Biology
• RNA Modification and Gene Regulation
• Cancer Therapeutics

Background:

• Fat mass and obesity-associated protein (FTO) is an Fe²⁺/2-oxoglutarate (2-OG)-dependent RNA demethylase.
• FTO overexpression is implicated in acute myeloid leukemia (AML) pathogenesis, partly via c-Myc upregulation.
• Targeting FTO presents a potential therapeutic strategy for AML.

Purpose of the Study:

• To develop a potent and selective FTO inhibitor.
• To investigate the therapeutic potential of FTO inhibition in AML.
• To design a cell-permeable FTO inhibitor prodrug.

Main Methods:

• Fragment linking of meclofenamic acid (MA) and 2-OG mimetics to create the FTO inhibitor 8a.
• Biochemical assays to assess FTO demethylation inhibition and selectivity.
• Synthesis and evaluation of the prodrug ester 8a-1 in AML cell lines and animal models.

Main Results:

• Compound 8a demonstrated potent and selective inhibition of FTO demethylation, outperforming its constituent fragments.
• The prodrug 8a-1 effectively suppressed AML cell viability, reduced global m⁶A levels, and modulated key gene expressions (c-Myc, CEBPA, ASB2, RARA).
• 8a-1 exhibited significant tumor-inhibiting efficacy in preclinical animal models.

Conclusions:

• 8a is a highly potent FTO inhibitor with a dual-competitive mechanism.
• The prodrug 8a-1 possesses therapeutic potential for AML by targeting FTO activity and downstream pathways.
• This study provides a promising framework for developing FTO-targeted therapies for AML.